What can clonal evolution in chronic lymphocytic leukemia (CLL) tell us about outcomes?

0 Views

07/08/23

Elias Campo, MD, PhD, from the University of Barcelona, Hospital Clinic, Barcelona, Spain, discusses clonal evolution in chronic lymphocytic leukemia (CLL) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He explains that while some tumors are homogenous, others have a great degree of heterogeneity. Dr Campo speaks about how different subclones display different mutations. According to Dr Campo, recent data indicate that homogenous tumors are associated with better outcomes. He also highlights the value of collaboration in understanding the complex biology of clonal evolution.